Company news

Lipocine Inc. news in 2020

Lipocine Inc.'s news releases, calls and decks from 2020, newest first.

View company

Lipocine Announces Open Label Extension to Ongoing LPCN 1144 LiFT Study

December 29, 2020

Lipocine Announces Update on Jury Trial in Patent Infringement Lawsuit Against Clarus Therapeutics

December 28, 2020

Lipocine Announces Tentative Approval of TLANDO™

December 7, 2020

Lipocine Announces Deletion of Unauthorized Changes to Company's Website

December 7, 2020

Lipocine Provides New Regulatory Update on TLANDO™

December 3, 2020

Lipocine Announces Third Quarter 2020 Financial and Operational Results

November 9, 2020

Lipocine Provides Regulatory Update on TLANDO™

November 5, 2020

Lipocine Announces Presentations at the 21st Annual Fall Meeting of the Sexual Medicine Society of North America

October 13, 2020

Lipocine Announces Completion of Enrollment in the LPCN 1144 LiFT Study

September 20, 2020

Lipocine Provides Regulatory Update for TLANDO™

August 27, 2020

Lipocine Announces Second Quarter 2020 Financial and Operational Results

August 5, 2020

Lipocine Announces Publication of LPCN 1144 Liver Fat Study ("LFS") Results

August 2, 2020

Lipocine Announces Derivative Suit Was Dismissed

July 30, 2020

Lipocine Regains Complinace With Nasdaq Minimum Bid Price Requirement

July 12, 2020

Lipocine Announces Presentations on TLANDO™ at AUA Virtual Experience 2020

May 14, 2020

Lipocine Announces First Quarter 2020 Financial and Operational Results

May 6, 2020

FDA Clears LPCN 1148 IND Application for Phase 2 Cirrhosis Trial

May 4, 2020

Lipocine Announces US Court of Appeals for the Federal Circuit Affirms Decision of USPTO

April 8, 2020

Lipocine Announces Outcome of Markman Hearing in Patent Infringement Suit Against Clarus

March 25, 2020

Lipocine Announces 2019 Year End Financial and Operational Results

March 12, 2020

Lipocine Announces TLANDO™ PDUFA Date of August 28, 2020

March 3, 2020

Lipocine Announces Closing Of Registered Direct Offering Of Common Stock And Warrants

February 26, 2020

Lipocine Announces $6 Million Registered Direct Offering Priced At-The-Market

February 24, 2020

Lipocine Announces Regulatory Path Forward for TLANDO™ Resubmission

February 23, 2020

Decks in 2020